TTOO
T2 Biosystems Inc is an in vitro diagnostic company. It has developed the proprietary platform that enables direct detection of pathogens, biomarkers and other abnormalities across various unpurified patient sample types.
T2 Biosystems, Inc. (TTOO) is rated C (2.2/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Growth (C+); its weakest is Revisions (D). The rating has held at C for 25 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2021-06-30 | C+ (2.5) | C+ (2.6) | C- (2.1) | C- (2.1) | D (1.5) | C (2.2) |
| 2020-12-31 | C+ (2.5) | A- (4.1) | D- (1.1) | C- (2.1) | D (1.5) | C (2.3) |
| 2020-09-30 | C+ (2.5) | C+ (2.5) | D+ (1.7) | C- (2.1) | D (1.4) | C- (2.1) |